CeriBell (NASDAQ:CBLL) executives said the company’s first-quarter results reflected continued momentum in both new account additions and increased usage among existing hospital customers, while outlining early progress in new clinical areas including neonatal seizure monitoring and delirium.
Speaking at a Bank of America healthcare conference, Scott Blumberg, CeriBell’s chief financial officer, said the company added 33 accounts in the first quarter, bringing its total to 680. He said that was the largest number of new additions since the company became public.
